Related Experiment Video

Updated: Jun 24, 2026

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)
10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

Selective cytostatic and cytotoxic anticancer effects of bisfunctional agents: A strategy for the design of DNA

Jarosław Spychała1

  • 1Adam Mickiewicz University, Department of Chemistry, Poznań, Poland. jspychala@wp.pl

Cancer Letters
|March 24, 2009
PubMed

Insights

Researchers explored novel anticancer drugs, focusing on molecular features for tumor cell selectivity. Specific cyclic amidinothymine analogues demonstrated potent, selective cytotoxicity against leukemia cell lines, translating to in vivo efficacy.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Anticancer drug development faces challenges with limited selectivity, leading to side effects.
  • Identifying molecular features essential for tumor cell selectivity is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To define molecular features essential for useful cytotoxicity by analyzing drug selectivity.
  • To investigate the in vitro and in vivo efficacy of novel anticancer agents.

Main Methods:

  • Synthesis and evaluation of cyclic amidinothymine analogues (NSC 697864, NSC 697865, NSC 697869) and bisfunctional agents (NSC 702408, NSC 702409).
  • Assessing nanomolar inhibitory activities against leukemia cell lines (CCRF-CEM, HL-60(TB)).
  • Analyzing molecular conformations and potential DNA interactions.

Main Results:

  • Selected cyclic amidinothymine analogues exhibited nanomolar inhibitory activity against leukemia cell lines.
  • Bisfunctional agents showed significant cytostatic and cytotoxic effects, with potential DNA interaction mechanisms.
  • In vitro selectivity correlated with in vivo efficacy, indicated by cumulative testing curves.

Conclusions:

  • Molecular selectivity is key to developing potent and less toxic anticancer drugs.
  • Novel cyclic amidinothymine analogues show promise as targeted leukemia therapies.
  • The study highlights the importance of structure-activity relationships in anticancer drug design.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...